D. Lawrence Wickerham, MD
Articles by D. Lawrence Wickerham, MD
In his article, Dr. Silverstein reviewsthe changing incidence of ductalcarcinoma in situ (DCIS) in theUnited States over the past 25 years,discusses the results of various clinicaltrials evaluating treatment optionsfor the disease, and, using the VanNuys Prognostic Index (VNPI), identifiesa subgroup of DCIS patientstreated by lumpectomy who, he feels,may be able to avoid breast irradiation.During several presentations atnational meetings, I have had the opportunityto debate Dr. Silverstein onthis topic. He is a powerful and articulateproponent of the idea thatcertain DCIS patients could be exemptedfrom radiation therapy withoutconsequences.
UFT Plus Calcium Folinate vs 5-FU Plus Calcium Folinate in Colon Cancer
ByRoy E. Smith, MD,D. Lawrence Wickerham, MD,H. Samuel Wieand, PhD,Linda Colangelo, MS,Eleftherios P. Mamounas, MD, MPH Adjuvant chemotherapy has been shown to alter the natural history of resected colon cancer. Two regimens (5-fluorouracil [5-FU] plus calcium folinate and 5-FU plus levamisole [Ergamisol]) have been found to prolong
Future Directions in the Adjuvant Treatment of Colon Cancer
ByEleftherios P. Mamounas, MD, MPH,H. Samuel Wieand, PhD,Judy Jones, MS,D. Lawrence Wickerham, MD,Norman Wolmark, MD Adjuvant chemotherapy has been shown to alter the natural history of patients with resected colon cancer. Two regimens (fluorouracil [5-FU] plus levamisole (Ergamisol) and 5-FU plus leucovorin) have been found most
